Janux Therapeutics (NASDAQ:JANX) Now Covered by Analysts at Jonestrading

Jonestrading began coverage on shares of Janux Therapeutics (NASDAQ:JANX) in a report published on Tuesday, Benzinga reports. The firm issued a buy rating and a $70.00 price target on the stock.

A number of other research firms have also weighed in on JANX. Cantor Fitzgerald assumed coverage on Janux Therapeutics in a research note on Wednesday, March 20th. They issued an overweight rating and a $100.00 target price on the stock. William Blair reiterated an outperform rating on shares of Janux Therapeutics in a research note on Tuesday, February 27th. Bank of America increased their target price on Janux Therapeutics from $24.00 to $48.00 and gave the stock a buy rating in a research note on Wednesday, March 13th. Wedbush restated an outperform rating and set a $53.00 price target on shares of Janux Therapeutics in a research note on Monday, March 11th. Finally, BTIG Research initiated coverage on Janux Therapeutics in a research note on Thursday, March 21st. They set a buy rating and a $62.00 price target on the stock. Seven investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has an average rating of Buy and an average target price of $61.33.

Janux Therapeutics Stock Down 2.5 %

Shares of JANX opened at $50.55 on Tuesday. The business has a fifty day moving average of $32.84 and a 200 day moving average of $17.39. Janux Therapeutics has a 52-week low of $5.65 and a 52-week high of $58.69. The company has a market cap of $2.61 billion, a PE ratio of -37.72 and a beta of 4.19.

Janux Therapeutics (NASDAQ:JANX) last released its earnings results on Friday, March 8th. The company reported ($0.25) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.37) by $0.12. Janux Therapeutics had a negative return on equity of 17.88% and a negative net margin of 721.18%. The business had revenue of $2.46 million for the quarter, compared to analyst estimates of $0.98 million. As a group, research analysts anticipate that Janux Therapeutics will post -1.41 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Janux Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the stock. Charles Schwab Investment Management Inc. boosted its position in Janux Therapeutics by 2.4% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 47,690 shares of the company’s stock valued at $628,000 after purchasing an additional 1,127 shares in the last quarter. Rhumbline Advisers boosted its position in Janux Therapeutics by 4.5% during the first quarter. Rhumbline Advisers now owns 26,849 shares of the company’s stock valued at $325,000 after purchasing an additional 1,158 shares in the last quarter. State of Wisconsin Investment Board boosted its position in Janux Therapeutics by 14.3% during the second quarter. State of Wisconsin Investment Board now owns 13,202 shares of the company’s stock valued at $157,000 after purchasing an additional 1,647 shares in the last quarter. American International Group Inc. boosted its holdings in Janux Therapeutics by 25.3% in the first quarter. American International Group Inc. now owns 8,813 shares of the company’s stock worth $126,000 after acquiring an additional 1,782 shares in the last quarter. Finally, Tower Research Capital LLC TRC boosted its holdings in Janux Therapeutics by 149.4% in the first quarter. Tower Research Capital LLC TRC now owns 3,344 shares of the company’s stock worth $40,000 after acquiring an additional 2,003 shares in the last quarter. Institutional investors own 75.39% of the company’s stock.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.